Form 4 for ALDX Aldeyra Therapeutics, Inc.
Accepted 2023-03-02 00:00:00 ET · period of report 2023-02-28 · accession 0000899243-23-006742 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-03-02 | 2023-02-28 | ALDX | Brady Todd C | Pres, CEO, Dir | A - Grant | $0.00 | +238.8K | 1.46M | +20% | $0 |
| D | 2023-03-02 | 2023-02-28 | ALDX | Brady Todd C | Pres, CEO, Dir | A - Grant | $0.00 | +250.0K | 250.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-28 | A | A | 238,750 | $0.00 | 1,455,285 | D | — | — | (F1) Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2023, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. |
| 2 | Derivative | Stock Option (right to buy) | 2023-02-28 | A | A | 250,000 | $0.00 | 250,000 | D | $6.76 · — to 2033-02-27 | 250,000 Common Stock | (F2) The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2023. |